0.09
-10.00%
Close of 3 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Invex Therapeutics
Its shares trade on ASX under the ticker IXC.AX. It has been listed since 5 July 2019. In the fiscal year to 30 June 2024, it reported revenue of A$1.7m and a net loss of A$1.6m. At that date it held total assets of A$6.1m and shareholders' equity of A$5.7m.
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2019-07-05. The firm is focused on developing treatments for neurological conditions and focused on developing treatments for neurological conditions. Its primary focus is Idiopathic Intracranial Hypertension (IIH), a condition of predominately overweight women of childbearing age, which can lead to disabling headaches and, in some patients, permanent vision loss. The company has completed a Phase II trial. The Company’s lead program is the development of Presendin for IIH. Presendin is a once-per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation developed by Peptron, Inc. The firm is conducting a Phase III clinical trial (IIH EVOLVE) designed to meet the requirements for market approval of Presendin for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Jul 2019
- Website
- invextherapeutics.com ↗
Leadership
Pay as last reported
- Mr. David McauliffeInterim Non-Executive Chairman of the BoardA$56,549
- Ms. Narelle WarrenChief Financial Officer, Company Secretary, since 2019A$143,097
- Ms. Carol ParishChief Operating Officer
- Dr. Thomas DuthyExecutive Director, since 2020A$263,864
- Mr. David WheelerNon-Executive Director
- Dr. Megan BaldwinNon-Executive Independent DirectorA$134,169
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Invex Therapeutics Ltd. completed a Phase II trial for Presendin targeting IIH.
- The company's lead program Presendin is a once-per week subcutaneous treatment for IIH.
- Invex Therapeutics is conducting a Phase III trial (IIH EVOLVE) in EU, UK, and Australia.
Weaknesses
- The company focuses on a narrow segment: Idiopathic Intracranial Hypertension (IIH) predominantly affecting overweight women.
- Invex Therapeutics has not yet received market approval for Presendin despite Phase III trials.
- The firm's primary focus on IIH limits its market scope to a specific patient population.
Opportunities
- The Phase III trial (IIH EVOLVE) could lead to market approval in the EU, UK, and Australia.
- Presendin's once-per week dosing offers a competitive advantage over daily treatments.
- Expanding to other neurological conditions could diversify Invex's portfolio beyond IIH.
Threats
- Permanent vision loss in IIH patients poses a significant health risk requiring urgent treatment.
- The condition primarily affects overweight women of childbearing age, limiting the target market size.
- Competition from other pharmaceutical treatments for neurological conditions remains a risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.